ClinicalTrials.gg
CompletedNCT05632744Updated Jul 2, 2026

Evaluation of CG-100 Intraluminal Bypass Device

An interventional study of CG-100 Intraluminal Bypass Device in Colorectal Cancer, sponsored by Colospan Ltd.. Completed at 1 site in Israel. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Colospan Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Colorectal Neoplasms with a site in Israel — 13 open to participants now, 22 under way, 5 of them phase 3. Colorectal Neoplasms · Israel.

Enrollment
76th of 78
7 · median 302
Started
2023
with 4 others
No phase
12 of 89
2 open now
Registered
75th of 89
by date

Among the 89 studies in Colorectal Neoplasms with a site in Israel, this one is the 76th largest by enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2023, is one of 12 with no phase, and was the 75th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

13 of the 89 studies in Colorectal Neoplasms with a site in Israel are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 22 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Colorectal Neoplasms with a site in Israel, or all of them as a file.
02

Study summary

Evaluation of CG-100 Intraluminal Bypass device

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (pre-operative):

  1. Willing to comply with protocol-specified follow-up evaluations
  2. 22-75 (inclusive) years of age at screening
  3. Diagnosed with colorectal cancer
  4. Has been informed of the nature of the study, agrees to its provisions, and has provided written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    CG-100 Intraluminal Bypass Device

    Subjects will be treated with CG-100 Intraluminal Bypass Device

    Device: CG-100 Intraluminal Bypass Device

Interventions

  • DeviceCG-100 Intraluminal Bypass Device

    Subjects will be treated with the CG-100 Intraluminal Bypass Device

06

What researchers measure

Primary outcomes

  1. Safety of the CG-100 Intraluminal Bypass Device

    Assessment of Serious Adverse Events

    Time frame: 10 days

Secondary outcomes

  1. Safety of the CG-100 Intraluminal Bypass Device

    Assessment of Serious Adverse Events

    Time frame: 4 weeks

07

Study locations

1 site
  • Soroka Medical Center
    Rehovot, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Apr 2024, 13 months.

Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's 13 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Dec 1, 2022
StartActual
Mar 15, 2023
Primary completionActual
Apr 15, 2024
CompletionActual
Apr 15, 2024
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05632744
Lead sponsor
Colospan Ltd.
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Mar 15, 2023
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024
Last update
Jul 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion